Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.90p 6.50p 7.30p 6.90p 6.90p 6.90p 8,068 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 15.3 -0.8 0.8 9.0 4.16

Venn Life Share Discussion Threads

Showing 1451 to 1472 of 1475 messages
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
DateSubjectAuthorDiscuss
25/5/2018
09:20
Just tried some digging on the reverse take over of Cellulac by Skin. Company director has 15 directorships of which 10 have ceased. Cellulac accounts last filed in 2016 & are long overdue. Can not find out without paying, whether Richardson is a shareholder or not. It as if all these guys blatantly pursue acquisitions as a way to hide their failings. What a murky world these men have created.
cocker
17/5/2018
12:58
I suggest everyone looks up the debate about EBITDA and its true or not so true representation of what a business is actually doing. Particularly as I bet that if you look at all the businesses that concentrate on quoting EBITDA and compare them with those that emphasise final profit, you'll get a big difference in performance. It all depends on what you think should or shouldn't be taken off EBITDA. imo EBITDA is a lifeline for businesses struggling to 'escape' exceptionals. "This is what my house would be worth, without the leaking roof and the ongoing legal case about the access road..."
yump
17/5/2018
11:03
Cheers AISHAH. I've also just found this from Davy, who forecast €1.1m EBITDA for this year: Https://www.davy.ie/research/public/article.htm?id=ST2_8081_1.xml.htm "FY results: margin expansion drives EBITDA growth May 17 2018 DAVY VIEW Venn has started to benefit from business integration initiatives and infrastructure investments made in 2017. Greater operational efficiency has driven margin expansion and EBITDA growth. With a full service capability spanning early and late phase clinical projects, we think there is scope to develop new business lines and further increase margins. Additionally, management focus on M&A opportunities has the potential to accelerate growth. We forecast FY 2018 EBITDA of €1.1m and remain ‘Outperform’."
rivaldo
17/5/2018
10:34
.@VennLifeScience (VENN) delivers a solid set of full year numbers. EBITDA more than doubling to €1.0m! In a very strong place to deliver on future growth. @HybridianLLP
aishah
17/5/2018
10:21
The results looked mildly encouraging. Turnover of €17.8m and €1.0m underlying EBITDA is certainly indicative of potential relative to a £4.3m m/cap if VENN's management continue to simplify and transform the company as they have been doing. Especially given they have €1.2m net cash to finance working capital and (from the tone of the narrative) an acquisition. I'd largely written Integumen off almost entirely except as a very long-term possibility, but I do like the look of its potential acquisition/reverse. Let's hope it actually completes (there's a radio silence on this at present, which may be a good or bad thing) - if it does this could just have a material effect on VENN. VENN's outlook is indeed difficult to discern, but perhaps there are clues for those looking for positives in the outlook given the focus on "improved underlying EBITDA", profitability and sunk investment costs which will hopefully pay off this year: "During 2017 our focus has been on the delivered improved underlying EBITDA in the business through improved operational efficiencies. Additional investment in systems means that we now have both the expertise and infrastructure to profitably execute new business in scale and our focus is now on the generation of new business opportunities. We have invested significantly in business development and engaged creatively with clients to develop deeper, longer lasting partnerships and our pipeline of opportunities is healthy. We continue to see an increasing number of opportunities that require the full range of services now on offer in Venn."
rivaldo
17/5/2018
09:24
zzzz just about covers it, a plodder rather than a growth share, they need rns'able material contract announcements to progress
elpirata
17/5/2018
07:51
Yes. 4 months gone and all there is, is the same old mention of 'opportunities'. Positively, it does look like the exceptional for the losses on Integumen covers just about all of it, so the next results should be 'clean'. Quick sanity check: if they ever make about £500,000 profit that would be about 0.8p earnings, which at this current share price would be a p/e of 10 ish.
yump
17/5/2018
07:30
Absolutely nothing on outlook. Very poor.
likitorma
17/5/2018
07:15
Given that the results have taken some 5 months to produce, very surprised no mention of current trading. zzzzzzzzzzzzzzzzzzzz
cocker
16/5/2018
12:08
just took a pop at this for results tomorrow buy showing as sell lol
elpirata
05/5/2018
18:05
I thought the idea was to say: "Don't you mean £18mln yump ? LOL" I didn't except the Spanish Inquisition
yump
04/5/2018
14:20
Not many can make profits on £18 turnover methinks Unless you charge staff £100k a year to work for you , and the BOD works for nothing Plus no biscuits with the tea break Apart from that , one of your better attempts 6/10 Re acquisition/s 1) no money to do so without raising cash or taking on debt 2) last one seems to have gone very badly yump23 Apr '18 - 07:29 - 1161 of 1161 0 0 0 I suspect that whatever the results deliver, the outlook will be rubbish. There hasn't been any contract announcement for ages and ages (Sedana was the last). That implies that there haven't been any material (to the market) ones. So they're just bumbling along with a collection of smaller projects. Hence, imo, the interest in more acquisitions, as organic hasn't done it. So more share placements, larger revenue from adding acquisitions and a hope for decent profits at some point. Which I think is unlikely as they haven't managed to make clean profits yet on £18 revenue - ie. the business doesn't appear to be viable.
buywell3
23/4/2018
07:29
I suspect that whatever the results deliver, the outlook will be rubbish. There hasn't been any contract announcement for ages and ages (Sedana was the last). That implies that there haven't been any material (to the market) ones. So they're just bumbling along with a collection of smaller projects. Hence, imo, the interest in more acquisitions, as organic hasn't done it. So more share placements, larger revenue from adding acquisitions and a hope for decent profits at some point. Which I think is unlikely as they haven't managed to make clean profits yet on £18 revenue - ie. the business doesn't appear to be viable.
yump
16/4/2018
11:14
http://cellulac.com/sf/ ...The team, which came from a previous successful company, Alltracel Pharmaceuticals, altered the direction and mission to address the glaring lack of infrastructure needed to commercialize the technology... theres the connection
elpirata
16/4/2018
11:05
Looks like a relentless seller having finally cleared and opportunistic buyers taking advantage - let's hope this bounce has some legs
gleach23
16/4/2018
11:03
RNS Integumen reverse takeover of Cellulac plc, who's last reported accounts show £1.5m investments on the balance sheet £7.5m funding raise
elpirata
16/4/2018
10:10
well elpitra maybe you should have acted and not hesitated but i have no idea why the share price has decided to rise from the dead!
ali47fish
13/4/2018
12:05
some trading activity today, I'm undecided whether to dip in - this should be the bottom reading the last trading statement but who knows whats lurking that they havent yet disclosed
elpirata
12/4/2018
10:27
why hasn't the company informed investors about this state of affairs with the share price in free fall- the last update from memory was not a disaster!
ali47fish
10/4/2018
20:38
Well I think we all most assume something is not right Arthur.
cocker
10/4/2018
18:26
unless anything has changed since that trading update I reckon its most likely a Cenkos led dilutive funding - cash Dec 17 was circa £1.04m vs. Dec 16 £2.965m its muddied by the FD departure, which strangely hasnt yet been notified on companies house director resignation despite it being 3 weeks ago to date. Unless of course he's 'resigned' as FD but continuing as a director?? Doesnt stack up.
elpirata
10/4/2018
07:19
TU on the 15/2 says otherwise Arthur. Lower revenue but broadly in line eps for 2017. Since then the Finance guy has jumped ship & results should have been out easily by now, so I guess this does not bode well for investors.
cocker
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180526 19:53:09